Last reviewed · How we verify
Caraminphen (CARAMIPHEN)
Caraminphen (generic name: CARAMIPHEN) is a caramiphen drug. It is currently FDA-approved.
Caraminphen is a small molecule medication. It is also known as Caramiphen HCl or Caramiphen Hydrochloride.
At a glance
| Generic name | CARAMIPHEN |
|---|---|
| Drug class | caramiphen |
| Target | Lysosomal Pro-X carboxypeptidase, Sigma non-opioid intracellular receptor 1, Muscarinic acetylcholine receptor M1 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Caraminphen CI brief — competitive landscape report
- Caraminphen updates RSS · CI watch RSS
Frequently asked questions about Caraminphen
What is Caraminphen?
Caraminphen (CARAMIPHEN) is a caramiphen drug.
What is the generic name of Caraminphen?
CARAMIPHEN is the generic (nonproprietary) name of Caraminphen.
What drug class is Caraminphen in?
Caraminphen belongs to the caramiphen class. See all caramiphen drugs at /class/caramiphen.
What development phase is Caraminphen in?
Caraminphen is FDA-approved (marketed).
What does Caraminphen target?
Caraminphen targets Lysosomal Pro-X carboxypeptidase, Sigma non-opioid intracellular receptor 1, Muscarinic acetylcholine receptor M1 and is a caramiphen.
Related
- Drug class: All caramiphen drugs
- Target: All drugs targeting Lysosomal Pro-X carboxypeptidase, Sigma non-opioid intracellular receptor 1, Muscarinic acetylcholine receptor M1
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing